Sign in
EARS Stock Price, Chart, Stats & News
Altamira Therapeutics Ltd.
Save
4.21M
Market cap
–
Current P/E
–
Forward P/E
EARS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -84.03% |
ROE | -111.64% |
D/E | 0.05x |
Interest coverage ratio | – |
EARS valuation
P/E | – |
P/S | – |
P/B | 0.02x |
P/CF | -0.02x |
P/FCF | -0.18x |
P/OCF | -0.02x |
PEG | -0.00x |
EV multiple | -0.37x |
About
The company is dedicated to creating innovative therapeutic solutions for pressing medical requirements within neurotology and central nervous system disorders. Based in Zug, Switzerland, the firm operates with a modest team of 11 full-time employees. A significant part of its developmental pipeline focuses on intranasal betahistine, specifically AM-125 for addressing vertigo and AM-201 for mitigating antipsychotic-induced weight gain and somnolence.
Similar securities
Based on sector and market capitalization
Report issue